Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ISRCTN40126490) titled 'Evaluating a new high-dose aflibercept injection for people with polypoidal choroidal vasculopathy that has not responded well to standard care' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: N/A: single arm study
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Treatment
Primary Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Condition:
Neovascular age-related macular degeneration
Polypoidal choroidal vasculopathy
Eye Diseases
Intervention:
The intervention is Aflibercept 8mg (Eylea 8mg) - Eylea 114.3 mg/ml solution for injection. Treatment is in a...